The tellurium‐based immunomodulator, AS101 ameliorates adjuvant‐induced arthritis in rats | Zendy

Halpert G. | Zendy; Halperin Sheinfeld M. | Zendy; Monteran L. | Zendy; Sharif K. | Zendy; Volkov A. | Zendy; Nadler R. | Zendy; Schlesinger A. | Zendy; Barshak I. | Zendy; Kalechman Y. | Zendy; Blank M. | Zendy; Shoenfeld Y. | Zendy; Amital H. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The tellurium‐based immunomodulator, AS101 ameliorates adjuvant‐induced arthritis in rats

Author(s) -

Halpert G.,

Halperin Sheinfeld M.,

Monteran L.,

Sharif K.,

Volkov A.,

Nadler R.,

Schlesinger A.,

Barshak I.,

Kalechman Y.,

Blank M.,

Shoenfeld Y.,

Amital H.

Publication year - 2021

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.13553

Subject(s) - medicine , arthritis , rheumatoid arthritis , proinflammatory cytokine , immune system , immunology , inflammation , adjuvant , synovial membrane , autoantibody , antibody

We report an anti‐rheumatic/inflammatory activity of the non‐toxic, tellurium‐based immunomodulatory compound AS101 in experimental RA by reducing disease progression, by blocking extravasation of inflammatory VLA4+ cells into the joint and by preservation of joint tissue architecture.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research